Harmony Biosciences (HRMY) vs Pharvaris N.V. (PHVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Harmony Biosciences (HRMY) has outperformed Pharvaris N.V. (PHVS) over the past year, gaining 45.4% versus a gain of 41.2%. Over five years, PHVS leads with a +100.5% price change compared with -0.2% for HRMY. Harmony Biosciences is the larger company by market cap ($2.29 billion vs $2.22 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRMY | PHVS |
|---|---|---|
| Share price | $39.34 | $31.68 |
| Market cap | $2.29B | $2.22B |
| 1-day change | -0.05% | +1.80% |
| YTD return | +5.13% | +14.16% |
| 1-year return | +45.43% | +41.18% |
| 5-year return | -0.15% | +100.51% |
| P/E ratio (TTM) | 12.69 | — |
| Forward P/E | 5.62 | — |
| EPS (TTM) | $3.10 | $-3.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.49 | $43.25 |
| 52-week low | $25.52 | $20.65 |
| Distance from 52-week high | -9.54% | -26.75% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +21.10% | +80.62% |
| Average volume | 893.96K | 740.93K |
| Shares outstanding | 58.24M | 70.20M |
| Employees | 293 | 148 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 148 employees
HRMY vs PHVS FAQ
Which is bigger, Harmony Biosciences or Pharvaris N.V.?
Harmony Biosciences (HRMY) is larger, with a market capitalization of $2.29B compared with $2.22B for Pharvaris N.V. (PHVS).
Which stock has performed better over the past year, HRMY or PHVS?
HRMY returned +45.43% over the past 12 months, compared with +41.18% for PHVS (price return, excluding dividends). Past performance does not predict future results.
Are Harmony Biosciences and Pharvaris N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.